Evidence map›Paper›PMID 20715091›Full record

ArticleThe Laryngoscope2010

Role of tumor necrosis factor-alpha in wound repair in human vocal fold fibroblasts.

Xia Chen, Susan L Thibeault

Abstract read
In one paragraph

Article in The Laryngoscope, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Exploring the anti-inflammatory potential of topical hyaluronic acid for vocal fold injury in a rat model.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  5. Probiotics in Postoperative Pain Management.Journal of personalized medicine · 2023
    Review
  6. Wound Healing and Antioxidant Properties ofAntioxidants (Basel, Switzerland) · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Marine drugs · 2020
    Article
  11. Article
  12. In vitro evaluation of anti-fibrotic effects of select cytokines for vocal fold scar treatment.Journal of biomedical materials research. Part B, Applied biomaterials · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Biochemical and Biological Attributes of Matrix Metalloproteinases.Progress in molecular biology and translational science · 2017
    Review
  17. Review
  18. Article
  19. Early Cellular Response to Radiation in Human Vocal Fold Fibroblasts.The Annals of otology, rhinology, and laryngology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xia ChenDivision of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Wisconsin Madison, Madison, Wisconsin 53705-2275, USA.
Susan L Thibeault
University of Wisconsin–Madison · US

Funding

Engineering the Vocal Fold MucosaR01DC004336 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI Susan Lynn Thibeault · 2000 to 2026
$14.6M
Safety & effectiveness of HA hydrogels in immortalized vocal fold fibroblast cellR21DC008428 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI THIBEAULT, SUSAN L · 2006 to 2007
$399k
NIDCD NIH HHS R01 DC004336NIDCD NIH HHS R01 DC4336NIDCD NIH HHS R21 DC008428
6 · The paper itself

Abstract

objectives/hypothesisTumor necrosis factor-alpha (TNF-alpha) is an inflammatory cytokine and apoptotic molecule that appears to be a mediator in inflammation and fibrosis. The objective of this investigation was to examine the effects of TNF-alpha on 3D Carbylan-GSX in vitro cultured human vocal fold fibroblasts (hVFFs), to provide insight into the mechanism responsible for the improved vocal fold wound healing that has been previous reported with Carbylan-GSX treatment. STUDY

designIn vitro cell culture.

methodshVFF were cultured in 3D Carbylan-GSX and on polystyrene with different dosages of TNF-alpha (0, 0.1, 1, 10, and 100 ng/mL) with and without 10% fetal bovine serum (FBS). hVFF response to TNF-alpha was characterized by morphology, proliferation rates, and gene transcript levels for matrix metalloproteinase 1 (MMP1), matrix metalloproteinase 2 (MMP2), tissue inhibitor of metalloproteinase 3 (TIMP3), collagen I, collagen III, fibronectin, and TNF-alpha receptor.

resultsIn 3D Carbylan-GSX, TNF-alpha inhibited hVFF proliferation in a dose-dependent manner. TNF-alpha (0.1-100 ng/mL) was shown to significantly downregulate TIMP3 and extracellular matrix-related mRNA transcript levels for collagen III and fibronectin and to upregulate MMP1 and MMP2 expression, resulting in increased MMP/TIMP3 ratios. TNF-alpha receptor expression was significantly upregulated in Carbylan-GSX compared to control polystyrene. Responses were more marked in 10% FBS culture.

conclusionsAfter vocal fold injury, locally injected Carbylan-GSX can enhance the role of TNF-alpha in remodeling the lamina propria layer of the vocal fold, accelerating wound healing. Carbylan-GSX has potential as a new therapeutic approach that may lead to better treatment of vocal fold wound healing.

Indexed as

Cell DivisionCells, CulturedCollagen Type ICollagen Type IIFibroblastsFibronectinsGelatinHumansHyaluronic AcidIn Vitro TechniquesMatrix Metalloproteinase 1Matrix Metalloproteinase 2Receptors, Tumor Necrosis FactorTissue Inhibitor of Metalloproteinase-3Tumor Necrosis Factor-alphaVocal Cordscarbylan-GSXCollagen Type ICollagen Type IIFibronectinsGelatinHyaluronic AcidMatrix Metalloproteinase 1Matrix Metalloproteinase 2Receptors, Tumor Necrosis FactorTissue Inhibitor of Metalloproteinase-3Tumor Necrosis Factor-alpha

Identifiers

PMID20715091
PMCPMC2965638
OpenAlexW2066556027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.